Skip to main content
Erschienen in: Pathology & Oncology Research 3/2008

01.09.2008 | Original Paper

K-ras Mutation, HPV Infection and Smoking or Alcohol Abuse Positively Correlate with Esophageal Squamous Carcinoma

verfasst von: Ioannis D. Lyronis, Stavroula Baritaki, Ioannis Bizakis, Elias Krambovitis, Demetrios A. Spandidos

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

The Ras/Raf/MEK/ERK (MAPK) signal transduction cascade is an important mediator of a number of cellular fates including growth, survival and apoptosis. The aim of this study was to determine the incidence of B-raf, Kirsten-ras (K-ras) and Neuroblastoma-ras (N-ras) gene mutations in esophageal squamous cell carcinoma (ESCC) in the Greek population. DNA was extracted from 30 ESCC and 32 normal esophageal specimens and screened for V600E B-raf, and K-ras/N-ras codon 12 mutations, by PCR-RFLP based analysis. Among the genes tested, only the heterozygous K-ras mutation was detected in 5 out of the 30 ESCC specimens (16%), whereas no mutation was found in the normal esophageal tissue (P < 0.022). The normal samples were screened negative for N-ras and V600E B-raf mutations. The increased risk of esophageal cancer was correlated with tobacco use (OR = 3.5, P < 0.023) and alcohol abuse (OR = 7.22, P < 0.001), accompanied with the high incidence of the k-ras codon 12 mutation (22%, OR = 1.77 and 21%, OR = 1.52), respectively. A similar positive association was seen in human papilloma virus (HPV)-infected patients (OR = 5.66, P < 0.003). Our overall findings demonstrate that the mutational activation of the K-ras gene, HPV infection and tobacco or alcohol abuse, can be considered independently or in combination as high risk factors for ESCC development.
Literatur
1.
Zurück zum Zitat Arber N, Shapira I, Ratan J et al (2000) Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology 118:1045–1050CrossRefPubMed Arber N, Shapira I, Ratan J et al (2000) Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology 118:1045–1050CrossRefPubMed
2.
Zurück zum Zitat Arora S, Mathew R, Mathur M et al (2001) Alterations in MDM2 in esophageal squamous cell carcinoma: relationship with p53 status. Pathol Oncol Res 7:203–208CrossRefPubMed Arora S, Mathew R, Mathur M et al (2001) Alterations in MDM2 in esophageal squamous cell carcinoma: relationship with p53 status. Pathol Oncol Res 7:203–208CrossRefPubMed
3.
Zurück zum Zitat Bosetti C, Gallus S, Garavello W et al (2006) Smoking cessation and the risk of oesophageal cancer: an overview of published studies. Oral Oncol 42:957–964CrossRefPubMed Bosetti C, Gallus S, Garavello W et al (2006) Smoking cessation and the risk of oesophageal cancer: an overview of published studies. Oral Oncol 42:957–964CrossRefPubMed
4.
Zurück zum Zitat Fenoglio-Preiser CM (1999) Gastrointestinal pathology. An atlas and text, 2nd edn. Lippincott-Raven, Philadelphia, pp 102–103 Fenoglio-Preiser CM (1999) Gastrointestinal pathology. An atlas and text, 2nd edn. Lippincott-Raven, Philadelphia, pp 102–103
5.
Zurück zum Zitat Chetty R, Simelane S (1999) p53 and cyclin A protein expression in squamous carcinoma of the oesophagus. Pathol Oncol Res 5:193–196CrossRefPubMed Chetty R, Simelane S (1999) p53 and cyclin A protein expression in squamous carcinoma of the oesophagus. Pathol Oncol Res 5:193–196CrossRefPubMed
6.
Zurück zum Zitat Cohen Y, Xing M, Mambo E et al (2003) BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625–627PubMedCrossRef Cohen Y, Xing M, Mambo E et al (2003) BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625–627PubMedCrossRef
7.
Zurück zum Zitat Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954CrossRefPubMed Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954CrossRefPubMed
8.
Zurück zum Zitat Ellis A, Field JK, Field EA et al (1994) Tylosis associated with carcinoma of the oesophagus and oral leukoplakia in a large Liverpool family—a review of six generations. Eur J Cancer B Oral Oncol 30:102–112CrossRef Ellis A, Field JK, Field EA et al (1994) Tylosis associated with carcinoma of the oesophagus and oral leukoplakia in a large Liverpool family—a review of six generations. Eur J Cancer B Oral Oncol 30:102–112CrossRef
10.
Zurück zum Zitat Fransen K, Klintenas M, Osterstrom A et al (2004) Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25:527–533CrossRefPubMed Fransen K, Klintenas M, Osterstrom A et al (2004) Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25:527–533CrossRefPubMed
11.
Zurück zum Zitat Garnett MJ, Marais R (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313–319CrossRefPubMed Garnett MJ, Marais R (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313–319CrossRefPubMed
12.
Zurück zum Zitat Kim IJ, Park JH, Kang HC et al (2003) Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet 114:118–120CrossRefPubMed Kim IJ, Park JH, Kang HC et al (2003) Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet 114:118–120CrossRefPubMed
13.
Zurück zum Zitat Lam AK (2000) Molecular biology of esophageal squamous cell carcinoma. Crit Rev Oncol Hematol 33:71–90CrossRefPubMed Lam AK (2000) Molecular biology of esophageal squamous cell carcinoma. Crit Rev Oncol Hematol 33:71–90CrossRefPubMed
14.
Zurück zum Zitat Lee SH, Lee JW, Soung YH et al (2003) BRAF and KRAS mutations in stomach cancer. Oncogene 22:6942–6945CrossRefPubMed Lee SH, Lee JW, Soung YH et al (2003) BRAF and KRAS mutations in stomach cancer. Oncogene 22:6942–6945CrossRefPubMed
15.
Zurück zum Zitat Lord RV, O'Grady R, Sheehan C et al (2000) K-ras codon 12 mutations in Barrett’s oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J Gastroenterol Hepatol 15:730–736CrossRefPubMed Lord RV, O'Grady R, Sheehan C et al (2000) K-ras codon 12 mutations in Barrett’s oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J Gastroenterol Hepatol 15:730–736CrossRefPubMed
16.
Zurück zum Zitat Lyronis ID, Baritaki S, Bizakis I et al (2005) Evaluation of the prevalence of human papillomavirus and Epstein–Barr virus in esophageal squamous cell carcinomas. Int J Biol Markers 20:5–10PubMed Lyronis ID, Baritaki S, Bizakis I et al (2005) Evaluation of the prevalence of human papillomavirus and Epstein–Barr virus in esophageal squamous cell carcinomas. Int J Biol Markers 20:5–10PubMed
17.
Zurück zum Zitat Mandard AM, Hainaut P, Hollstein M (2000) Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res 462:335–342CrossRefPubMed Mandard AM, Hainaut P, Hollstein M (2000) Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res 462:335–342CrossRefPubMed
18.
Zurück zum Zitat Mercer KE, Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653(1):25–40, Jun 5PubMed Mercer KE, Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653(1):25–40, Jun 5PubMed
19.
Zurück zum Zitat Ramachandran S, Ramadas K, Hariharan R et al (2006) Single nucleotide polymorphisms of DNA repair genes XRC1 and XPD and its molecular mapping in Indian oral cancer. Oral Oncol 42:350–362CrossRefPubMed Ramachandran S, Ramadas K, Hariharan R et al (2006) Single nucleotide polymorphisms of DNA repair genes XRC1 and XPD and its molecular mapping in Indian oral cancer. Oral Oncol 42:350–362CrossRefPubMed
20.
Zurück zum Zitat Scully C, Field JK, Tanzawa H (2000) Genetic aberrations in oral or head and neck squamous cell carcinoma 2: chromosomal aberrations. Oral Oncol 36:311–327CrossRefPubMed Scully C, Field JK, Tanzawa H (2000) Genetic aberrations in oral or head and neck squamous cell carcinoma 2: chromosomal aberrations. Oral Oncol 36:311–327CrossRefPubMed
21.
Zurück zum Zitat Sommerer F, Vieth M, Markwarth A et al (2004) Mutations of BRAF and KRAS2 in the development of Barrett’s adenocarcinoma. Oncogene 23:554–558CrossRefPubMed Sommerer F, Vieth M, Markwarth A et al (2004) Mutations of BRAF and KRAS2 in the development of Barrett’s adenocarcinoma. Oncogene 23:554–558CrossRefPubMed
22.
Zurück zum Zitat Spandidos DA, Sourvinos G, Tsatsanis C et al (2002) Normal ras genes: their onco-suppressor and pro-apoptotic functions (review). Int J Oncol 21:237–241PubMed Spandidos DA, Sourvinos G, Tsatsanis C et al (2002) Normal ras genes: their onco-suppressor and pro-apoptotic functions (review). Int J Oncol 21:237–241PubMed
23.
24.
Zurück zum Zitat Talamini G, Capelli P, Zamboni G et al (2000) Alcohol, smoking and papillomavirus infection as risk factors for esophageal squamous-cell papilloma and esophageal squamous-cell carcinoma in Italy. Int J Cancer 86:874–878CrossRefPubMed Talamini G, Capelli P, Zamboni G et al (2000) Alcohol, smoking and papillomavirus infection as risk factors for esophageal squamous-cell papilloma and esophageal squamous-cell carcinoma in Italy. Int J Cancer 86:874–878CrossRefPubMed
25.
Zurück zum Zitat Tavani A, Bertuzzi M, Talamini R et al (2003) Coffee and tea intake and risk of oral, pharyngeal and esophageal cancer. Oral Oncol 39:695–700CrossRefPubMed Tavani A, Bertuzzi M, Talamini R et al (2003) Coffee and tea intake and risk of oral, pharyngeal and esophageal cancer. Oral Oncol 39:695–700CrossRefPubMed
26.
Zurück zum Zitat Wang WKP, Schwartz M, Malon G et al (1994) PCR amplification of 40 year-old paraffin-embedded tumour tissues: comparison of four different DNA extraction and purification methods. Int J Oncol 5:0–4 Wang WKP, Schwartz M, Malon G et al (1994) PCR amplification of 40 year-old paraffin-embedded tumour tissues: comparison of four different DNA extraction and purification methods. Int J Oncol 5:0–4
27.
Zurück zum Zitat Weber A, Langhanki L, Sommerer F et al (2003) Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 22:4757–4759CrossRefPubMed Weber A, Langhanki L, Sommerer F et al (2003) Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 22:4757–4759CrossRefPubMed
28.
Zurück zum Zitat Wu M, Semba S, Oue N et al (2004) BRAF/K-ras mutation, microsatellite instability, and promoter hypermethylation of hMLH1/MGMT in human gastric carcinomas. Gastric Cancer 7:246–253CrossRefPubMed Wu M, Semba S, Oue N et al (2004) BRAF/K-ras mutation, microsatellite instability, and promoter hypermethylation of hMLH1/MGMT in human gastric carcinomas. Gastric Cancer 7:246–253CrossRefPubMed
Metadaten
Titel
K-ras Mutation, HPV Infection and Smoking or Alcohol Abuse Positively Correlate with Esophageal Squamous Carcinoma
verfasst von
Ioannis D. Lyronis
Stavroula Baritaki
Ioannis Bizakis
Elias Krambovitis
Demetrios A. Spandidos
Publikationsdatum
01.09.2008
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2008
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9032-1

Weitere Artikel der Ausgabe 3/2008

Pathology & Oncology Research 3/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.